Trial Profile

Phase II study comparing BCD-085 head-to-head with another IL-17 inhibitor.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 02 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Netakimab (Primary) ; Interleukin 17 inhibitors
Indications Ankylosing spondylitis; Plaque psoriasis
Focus Therapeutic Use

Most Recent Events

02 May 2018 New trial record
26 Apr 2018 According to Biocad media release, company plans to initiate this trial in 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com